#Merck

Merck’s investigational antiretroviral could one day be dosed only weekly among HIV-negative humans.

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

The new drug application is for doravirine as both an individual tablet and part of a combination tablet.

Merck’s hepatitis C treatment cured almost all those with stages 3 through 5 of chronic kidney disease in a VA database.

The president tweeted a swift retort to the African-American head of Merck.

Until now, Isentress (raltegravir) had been available only as a twice-daily drug.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Used as a part of a multidrug HIV regimen, the investigational doravirine is also better for cholesterol levels than Norvir/Prezista.

The U.S. Food and Drug Administration (FDA) has approved Merck’s once-daily fixed-dose combination tablet Zepatier (grazoprevir/elbasvir)

Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.

Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Cutting through the hype and hyperbole.